SCHEMBL6000108

SCHEMBL6000108

O=C(O)c1ccc(CNCc2nc(-c3ccc(CNc4ccc(C5CCCCC5)cc4)cc3)cs2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRE11 P49959 1/20 0.41
ROCK2 O75116 1/20 0.40
GRK2 P25098 1/20 0.40
RAB9A P51151 6/20 0.39
NPC1 O15118 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
KDM4E B2RXH2 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
GAA P10253 2/20 0.39
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
TRPA1 O75762 1/20 0.39
CSNK2A1 P68400 2/20 0.39
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
CPT1B Q92523 1/20 0.38
NAMPT P43490 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6000640 0.94 MRE11 (0.44) MRE11ROCK2GRK2RAB9ANPC1
SCHEMBL5999047 0.91 HDAC3 (0.50) MRE11RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5999739 0.87 MRE11 (0.40) MRE11ROCK2GRK2RAB9ANPC1
SCHEMBL5999835 0.87 HRH3 (0.45) MRE11RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL6000469 0.86 HDAC8 (0.53) MRE11ROCK2GRK2RAB9ANPC1
SCHEMBL6000178 0.86 HRH3 (0.44) MRE11ROCK2GRK2RAB9ANPC1
SCHEMBL6000636 0.85 RXRA (0.39) MRE11RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL6001067 0.84 RAB9A (0.42) MRE11RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5585757 0.82 CPB1 (0.39) MRE11RAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL5585653 0.82 RAB9A (0.41) MRE11RAB9ANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US claimed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP claimed
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-06-08 US disclosed
EP-1553091-A1 HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122181-A1 Heteroaromatic pentacyclic compound and medicinal use thereof PTPN11, PTPN1, PTPN3 MRE11 4881/4885ROCK2 1672/4885GRK2 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.